Antibodies assembled after RenLite discovery have a traditional antibody structure with properties that are advantageous for downstream CMC development.
$60 million Series A financing to support clinical development of portfolio of KIF18A inhibitors and programs targeting chromosomally unstable cancers.
Gains non-exclusive rights to use the CAP Ad platform for the manufacturing of adeno-based vaccines for prophylactic and therapeutic use in infectious diseases.
GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharma and financial subsidiaries.